Teva names Matthew Shields to executive VP, global operations role
Teva has appointed Matthew Shields as executive vice president of Teva Global Operations, the company’s manufacturing and supply division, effective June 3.
Shields succeeds Eric Drapé, who is leaving after 11 years with the company, including more than four years as executive vice president of global operations.
Shields will be a member of Teva’s executive leadership team and report directly to president and CEO Richard Francis. He will be based in Teva’s U.S. headquarters in Parsippany, N.J.
Shields joins Teva with a track record over a 25-plus year career in the global biopharmaceutical and animal health industries. As an engineer by trade, Shields brings significant experience at every stage of the manufacturing and supply process. Most recently, Shields served as senior vice president for Animal Health Manufacturing for Merck, known as MSD Animal Health outside of the United States and Canada, where he oversaw end-to-end manufacturing, supply chain, procurement and process development. Prior to Merck, he led Specialty Care Manufacturing, Engineering and Operational Excellence for Sanofi.
[Read more: Teva rolls out generic Nexavar tablets]
Shields spent much of his early career at Amgen, where held a variety of leadership roles in operations.
Richard Francis, Teva's president and CEO said, “I’m thrilled to welcome a transformational leader of Matthew’s caliber to the executive team at Teva. Matthew brings a wealth of experience in health operations that are critical to fulfilling our purpose by enabling Teva to execute on our promises to patients and healthcare systems around the world. Matthew is ideally positioned to lead our TGO organization through the next phase of our Pivot to Growth journey.”
Francis added, “As we have intensified our efforts to best position Teva for future success through our Pivot to Growth strategy, Eric Drapé has played a key role in strengthening our operations network. During his tenure leading TGO, the organization has made tremendous strides serving patients by standardizing processes, increasing agility, and improving our operating margin. I would like to thank Eric for his many contributions to Teva and wish him all the best as he embarks on a new and exciting phase in his life.”
[Read more: Teva obtains FDA nod for generic Forteo]
Shields said, “Teva is clearly a company with incredible potential based on the early progress of its Pivot to Growth strategy, and its tremendous heritage in manufacturing important medicines serving the needs of patients around the world. I’m honored to take on this critical role, and eager to begin working with the talented team in Teva Global Operations, and my colleagues across the Company, to deliver on our inspiring purpose.”